TITLE:
A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3

CONDITION:
HIV Infections

INTERVENTION:
Ranitidine hydrochloride

SUMMARY:

      To evaluate the effect of ranitidine on immunologic indicators in asymptomatic HIV-1
      infected patients with CD4 counts of 400-700 cells/mm3.
    

DETAILED DESCRIPTION:

      Patients are randomized to receive either ranitidine or matching placebo bid for 16 weeks,
      with follow-up every 4 weeks through week 20.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have:

          -  Asymptomatic HIV-1 infection.

          -  CD4 count of 400-700 cells/mm3.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Significant illness.

          -  Acute illness at randomization.

          -  Hemodialysis.

        Prior Medication:

        Excluded:

          -  Antiretroviral use within 60 days prior to study entry.
      
